Paysign price target raised to $4.50 from $3.50 at Maxim

Maxim raised the firm’s price target on Paysign to $4.50 from $3.50 and keeps a Buy rating on the shares. The company’s Q4 results were just below consensus, but the initial 2023 guidance was "strong", the analyst tells investors in a research note. The firm adds that a court decision in mid-September now allows individuals with tourist visas to donate plasma, and this should increase visits to plasma centers along the Mexican border that are serviced by Paysign.